Abstract OT3-4-01: A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (JCOG1017 study; PRIM-BC)

医学 全身疗法 临床终点 乳腺癌 转移性乳腺癌 内科学 癌症 随机对照试验 肿瘤科 随机化 代理终结点 原发性肿瘤 外科 转移
作者
Tadahiko Shien,Hiroji Iwata,Kenichi Nakamura,Takayuki Kinoshita,Fumikata Hara,Tomomi Fujisawa,Norikazu Masuda,Kenichi Inoue,Taro Shibata,Haruhiko Fukuda
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:75 (9_Supplement): OT3-01
标识
DOI:10.1158/1538-7445.sabcs14-ot3-4-01
摘要

Abstract A brief background discussion: The efficacy and indication of primary tumour resection for breast cancer patients with distant metastases are under debate. There were many retrospective analysis reports indicating the survival benefit of it. However, the first results of two randomized studies reported in SABCS 2013 could not demonstrate the survival benefit. Nevertheless, the results were not conclusive because the systemic therapy was not uniform (e.g. molecular target therapy) and the diagnostic procedures of metastases was different from the widely accepted guidelines. Trial design: Our trial is being conducted to confirm the superiority, in terms of the overall survival, of surgery plus systemic therapy over systemic therapy alone in stage IV patients who are not refractory to primary systemic therapy (PST). Eligibility criteria: The inclusion criteria for the study are as follows: untreated patients with histologically confirmed invasive breast cancer with one or more measurable distant metastatic lesions diagnosed by radiological examination. Specific aims: All patients receive PST according to the ER and HER2 status of the primary breast cancer after the first registration. After three months, the patients without disease progression are randomized to the primary tumour resection plus systemic therapy arm or the systemic therapy alone arm. After randomization and surgery in the former arm, or after randomization in the latter arm, the same systemic therapies are continued until progression of diseases and next appropriate regimens are started after that. Statistical methods: The primary endpoint is the overall survival, and the secondary endpoints are proportion of patients without tumour progression at the metastatic sites, yearly local recurrence-free survival, proportion of local ulcer/local bleeding, yearly primary tumour resection-free survival, adverse events of chemotherapy, operative morbidity, and serious adverse events. Sample size for randomized patients was determined to attain at least 80% of power to detect a 6 months difference with one-sided alpha of 0.05. Present accrual and target accrual: The patient recruitment was started in May 2011. Enrolment of 410 patients for randomization is planned over a 5-year recruitment period. More than two hundred twenty patients were already enrolled until May 2014. Citation Format: Tadahiko Shien, Hiroji Iwata, Kenichi Nakamura, Takayuki Kinoshita, Fumikata Hara, Tomomi Fujisawa, Norikazu Masuda, Kenichi Inoue, Taro Shibata, Haruhiko Fukuda. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (JCOG1017 study; PRIM-BC) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr OT3-4-01.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
彭于晏应助weerfi采纳,获得10
刚刚
隐形曼青应助正在进行时采纳,获得10
1秒前
海东来应助高大的天道采纳,获得50
1秒前
开放飞阳完成签到,获得积分10
1秒前
科研通AI2S应助帅气凝云采纳,获得10
1秒前
Deny完成签到,获得积分10
1秒前
orixero应助Elliot_315采纳,获得10
1秒前
2秒前
2秒前
sugar完成签到,获得积分10
2秒前
JamesPei应助张灬小胖采纳,获得10
3秒前
王小小完成签到,获得积分10
3秒前
Cheung2121完成签到,获得积分20
3秒前
4秒前
4秒前
kelly完成签到,获得积分10
4秒前
共享精神应助JM采纳,获得10
4秒前
坦率的匪举报111求助涉嫌违规
5秒前
长情的千风完成签到,获得积分10
5秒前
5秒前
woshiwuziq完成签到 ,获得积分10
6秒前
anna1992发布了新的文献求助10
7秒前
YY完成签到,获得积分10
7秒前
符宇新发布了新的文献求助10
7秒前
iNk应助kk采纳,获得10
8秒前
小马甲应助有机分子笼采纳,获得10
8秒前
8秒前
8秒前
张文静发布了新的文献求助30
8秒前
沉默的小天鹅应助xiaose采纳,获得10
9秒前
章宇完成签到,获得积分10
9秒前
充电宝应助123采纳,获得10
10秒前
想喝冰美完成签到,获得积分10
10秒前
bkagyin应助小海采纳,获得10
10秒前
帅气凝云完成签到,获得积分10
10秒前
LUKW给嘟嘟喂嘟嘟的求助进行了留言
10秒前
10秒前
清新的寄风完成签到 ,获得积分10
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Handbook of Marine Craft Hydrodynamics and Motion Control, 2nd Edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3987078
求助须知:如何正确求助?哪些是违规求助? 3529488
关于积分的说明 11245360
捐赠科研通 3267987
什么是DOI,文献DOI怎么找? 1804013
邀请新用户注册赠送积分活动 881270
科研通“疑难数据库(出版商)”最低求助积分说明 808650